Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating glecaprevir/pibrentasvir in treatment-naive adults with chronic HCV genotypes 1-6 in Brazil completed with posted results in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Glecaprevir/pibrentasvir (glecaprevir/pibrentasvir)

Snippet

Sponsor: AbbVie | Conditions: Hepatitis C Virus (HCV) | Phase 3 | Status: COMPLETED | Results posted: 2020-03-17